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Introduction
Cladribine is an oral, synthetic deoxyadenosine analog 
prodrug, which preferentially depletes lymphocytes 
by exploiting the kinase-to-phosphatase enzyme pro-
file in these cells. This produces moderate and discon-
tinuous reductions in T and B cells with relatively 
minor and transient effects on innate immune cells, 
such as neutrophils and monocytes.1 The dosing regi-
men of cladribine tablets involves very short treatment 
periods relative to the length of clinical effect 
(8–10 days annually).2 In the Cladribine Tablets 
Treating Multiple Sclerosis Orally (CLARITY) study 
(ClinicalTrials.gov, NCT00213135), patients with 
active relapsing–remitting multiple sclerosis (RRMS) 
were randomized to placebo or one of two cumulative 
doses of cladribine tablets (3.5 or 5.25 mg/kg body 
weight) for 2 years; each dose showed significant 
benefits in rate of relapse, disability progression, and 
magnetic resonance imaging (MRI) measures.2 The 
most commonly reported adverse event (AE) was mild 
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Abstract
Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical and mag-
netic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing–remitting multiple scle-
rosis (MS).
Objective: To assess the safety and efficacy of cladribine treatment in a 2-year Extension study.
Methods: In this 2-year Extension study, placebo recipients from CLARITY received cladribine 
3.5 mg/kg; cladribine recipients were re-randomized 2:1 to cladribine 3.5 mg/kg or placebo, with blind 
maintained.
Results: A total of 806 patients were assigned to treatment. Adverse event rates were generally similar 
between groups, but lymphopenia Grade ⩾ 3 rates were higher with cladribine than placebo (Grade 4 
lymphopenia occurred infrequently). In patients receiving cladribine 3.5 mg/kg in CLARITY and expe-
riencing lymphopenia Grade ⩾ 3 in the Extension, >90% of those treated with cladribine 3.5 mg/kg and 
all treated with placebo in the Extension, recovered to Grade 0–1 by study end. Cladribine treatment in 
CLARITY produced efficacy improvements that were maintained in patients treated with placebo in 
the Extension; in patients treated with cladribine 3.5 mg/kg in CLARITY, approximately 75% remained 
relapse-free when given placebo during the Extension.
Conclusion: Cladribine tablets treatment for 2 years followed by 2 years’ placebo treatment produced 
durable clinical benefits similar to 4 years of cladribine treatment with a low risk of severe lymphopenia 
or clinical worsening. No clinical improvement in efficacy was apparent following further treatment with 
cladribine tablets after the initial 2-year treatment period in this trial setting.
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to moderate lymphopenia, reflecting the mode of 
action of cladribine.2
Here, we report findings from the CLARITY Extension 
study (ClinicalTrials.gov, NCT00641537), which 
investigated long-term safety, tolerability, and clinical 
benefits following administration of placebo or a 
cumulative dose of cladribine tablets 3.5 mg/kg body 
weight in patients who had completed CLARITY. The 
design allowed assessment of the effects of 2 years’ 
additional treatment with cladribine tablets beyond 
the 2-year CLARITY regimen and included an 
assessment of the duration of the therapeutic benefit 
by a comparison of 2 years’ treatment with cladribine 
tablets followed by 2 years of placebo, and 2 years’ 
treatment with cladribine tablets followed by two 
additional years of cladribine tablets treatment. In 
addition, early vs late treatment was compared by 
including a group receiving 2 years’ placebo treatment 
followed by 2 years’ cladribine tablets treatment.
Methods
Patients
Patients who completed the 2-year study period in 
CLARITY were eligible for the Extension if they 
had normal lymphocyte count and other normal 
hematological results within 28 days of the first 
planned dose (see Supplementary Materials). 
CLARITY Extension was not a pre-planned study, 
and as a consequence after completing CLARITY, 
there was a variable gap period before patients entered 
the Extension (the median gap duration for the 
overall population was 40.3 weeks). Patients who had 
received interferon beta or glatiramer acetate during 
the gap period had to discontinue their disease- 
modifying drug (DMD) therapy ⩾3 months before 
the first study day of the Extension.
Randomization and masking
Patients who entered the Extension were 
re-randomized using an interactive voice response 
system. Randomization and double-blinding followed 
CLARITY procedures2 (see Supplementary Materials). 
The on-study treatment groups were as follows:
•• CP 3.5 mg/kg (cladribine tablets 3.5 mg/kg in 
CLARITY/placebo in CLARITY Extension);
•• CP 5.25 mg/kg (cladribine tablets 5.25 mg/kg 
in CLARITY/placebo in CLARITY Extension);
•• CC 7 mg/kg (cladribine tablets 3.5 mg/kg in 
CLARITY/cladribine tablets 3.5 mg/kg in 
CLARITY Extension);
•• CC 8.75 mg/kg (cladribine tablets 5.25 mg/kg 
in CLARITY/cladribine tablets 3.5 mg/kg 
CLARITY Extension);
•• PC 3.5 mg/kg (placebo in CLARITY/cladrib-
ine tablets 3.5 mg/kg in CLARITY Extension).
Procedures
The study design is represented in Figure 1. Patients 
in CLARITY were randomized (1:1:1 ratio) to one of 
two cumulative doses of cladribine tablets or placebo, 
taking one or two cladribine 10-mg tablets (or match-
ing placebo) daily over 4–5 days in either Weeks 1 
and 5 of Years 1 and 2 (to give a cumulative dose of 
3.5 mg/kg) or Weeks 1, 5, 9, and 13 of Year 1 and Weeks 
1 and 5 of Year 2 (giving a 5.25 mg/kg cumulative 
dose).2 In the 96-week CLARITY Extension study, 
eligible patients who received placebo in CLARITY 
were assigned to cladribine tablets 3.5 mg/kg, and 
patients treated with cladribine tablets in CLARITY 
were re-randomized (2:1) to cladribine tablets 3.5 mg/
kg or placebo. Treating physicians supervised study 
drug administration and monitored safety assessments 
including laboratory parameters and were responsible 
for the recording and treatment of AEs and MS 
relapses, whereas separate evaluating physicians 
assessed neurological findings and relapses (each was 
blinded to treatment group assignment). The blind was 
maintained from CLARITY in all treatment arms dur-
ing the Extension. All patients treated with cladribine 
tablets during the Extension received a cumulative 
dose of 3.5 mg/kg, administered in Weeks 1, 5, 48, and 
52 (only patients with Grade 0 or 1 lymphocyte counts 
were retreated at Weeks 48 and 52). The Extension 
was followed by a 24-week “supplemental follow-up” 
(SUPF) during which patients did not receive treat-
ment with cladribine tablets but could receive DMDs.
Endpoints
Safety and clinical endpoints, including amendments, 
are described in the Supplementary Materials. Clinical 
endpoints included the annualized relapse rate (ARR), 
the proportion of patients free of qualifying relapses, 
time to first qualifying relapse, and time to confirmed 
Expanded Disability Status Scale (EDSS) progression.
Statistical analysis
No sample size calculation was made as enrollment 
was limited to eligible patients from CLARITY. 
No hypotheses were pre-specified in the original 
protocol, but an amendment specified a benefit/ 
risk analysis and a 2.5% significance level for the 
interim and final analyses. Efficacy endpoints were 
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exploratory and all determinations of significance 
were nominal; a p value ⩽0.025 was considered 
nominally significant.
To investigate potential incremental effects of extended 
treatment during the Extension, comparisons between 
groups included CP 3.5 mg/kg vs PC 3.5 mg/kg (early 
vs late treatment with the 3.5 mg/kg dose), CC 7 mg/kg 
vs CP 3.5 mg/kg, CC 8.75 mg/kg vs CP 5.25 mg/kg 
(192 weeks of treatment vs 96 weeks of treatment), and 
CC 7 mg/kg + CC 8.75 mg/kg (combined data for 
patients who received treatment with cladribine tablets 
in CLARITY and CLARITY Extension) vs CP 3.5 mg/
kg + CP 5.25 mg/kg (combined data for placebo in 
Years 3 and 4).
The intention-to-treat (ITT) population, which com-
prised patients randomized or assigned to treatment in 
the Extension, was analyzed for efficacy. The safety 
population, which included patients who received 
⩾one dose of study medication and had follow-up 
safety data, was analyzed for safety. Patients who had 
completed CLARITY but were not eligible for treat-
ment in the Extension were followed for safety only 
(SAFUP population).
Results
Patients
There were 1326 patients randomized into the 
CLARITY trial, of which, 1184 completed (89.3%). Of 
the 1184 that completed the CLARITY trial, 867 were 
enrolled in the Extension (73.2%, from 16 January 
2008 to 20 July 2009). Of the 867 enrolled in the 
Extension, 61 comprised the SAFUP population, and 
806 were randomized or assigned to treatment. The 
CLARITY study consisted of a total of 155 study sites; 
however, 22 fewer study sites were involved in 
CLARITY Extension. In total, there were five treat-
ment groups in CLARITY Extension (CP 3.5 mg/kg, 
n = 98; CP 5.25 mg/kg, n = 92; CC 7 mg/kg, n = 186; 
CC 8.75 mg/kg, n = 186; and PC 3.5 mg/kg, n = 244). 
These patients comprised the ITT population and quali-
fied for the safety population. In CLARITY Extension, 
806 patients were treated, of which 738 (91.6%) com-
pleted the 2-year study (Figure 2), and 636 (78.9%) 
entered the SUPF. The characteristics of patients who 
entered the Extension were similar across groups at 
baseline, except that patients who had received placebo 
in CLARITY showed evidence of greater disease activ-
ity (Table 1). The characteristics of patients who did or 
Figure 1. Study design. Each short course of treatment comprised one or two 10-mg cladribine tablets taken once daily 
for four or five consecutive days or an equivalent number of matching placebo tablets. There was a variable interval 
between the treatment periods in the CLARITY and Extension studies.
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine 
tablets 5.25 mg/kg in CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY 
followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed 
by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in 
CLARITY Extension; SUPF, supplemental follow-up.
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did not enter CLARITY Extension at baseline of the 
CLARITY study were also similar (Supplementary 
Table 1). The gap between CLARITY and the Extension 
varied within each group but was distributed similarly 
across the treatment groups. Relapses during the gap 
period were not qualified by an evaluating physician. 
There were no major differences between groups in 
disease management during the gap period with few 
patients receiving other DMDs (Table 1). Details for 
concomitant DMD use during the gap between 
CLARITY and Extension and during the SUPF are 
shown in the Supplementary Materials.
Safety outcomes
The incidence of AEs was generally similar between 
groups (Table 2), and most AEs were classified as 
mild or moderate. There were 89 (11.0%) treatment 
discontinuations due to AEs (Table 2 and 
Supplementary Table 2) but only 11 (1.4%) patients 
withdrew from the study due to AEs (not shown). 
During the Extension, the frequency of lymphopenia 
and leukopenia was higher in patients treated with 
cladribine tablets compared with placebo recipients. 
For patients who received cladribine tablets 3.5 mg/kg 
in both CLARITY and the Extension, the treatment 
discontinuation rate due to lymphopenia and the inci-
dence of lymphopenia AEs was somewhat elevated 
compared to patients who had received placebo in 
CLARITY and cladribine tablets in the Extension 
(Table 2). The majority of patients in each treatment 
group had no platelet toxicity, and among patients 
with decreased platelet count, most cases were Grade 
1 or 2 in severity. One patient in each of the CC 7 mg/kg 
and CC 8.75 mg/kg groups had ⩾Grade 3 platelet 
toxicity, but there were none in any other group (not 
shown). A total of 94 (11.7%) patients experienced 
⩾one serious adverse event (SAE), including 
infections and infestations (n = 16, 2.0%), and 
gastrointestinal disorders (n = 8, 1.0%).
AEs of special interest
Lymphopenia events of Grade ⩾ 3 were reported in all 
treatment groups, including approximately 6% of 
patients treated with placebo (Table 3). No patients in 
either the CP 3.5 or 5.25 mg/kg group experienced 
Grade 4 lymphopenia. In the CP 3.5 mg/kg group, 
five patients experienced Grade ⩾ 3 lymphopenia, 
and all recovered to Grade 0–1 lymphocyte counts 
during the Extension, with a mean (standard 
deviation (SD)) time to recovery of 41.0 (33.5) days 
Figure 2. Patient disposition during the CLARITY Extension study. Seven patients received rescue therapy during the 
2-year treatment period (CP 3.5 mg/kg, n = 3 (3.1%); CP 5.25 mg/kg, n = 2 (2.2%); CC 7 mg/kg, n = 1 (0.5%); PC 3.5 mg/
kg, n = 1 (0.4%)).
AE: adverse event; CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/
kg: cladribine tablets 5.25 mg/kg in CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in 
CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY 
followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/kg: placebo in CLARITY followed by cladribine tablets 
3.5 mg/kg in CLARITY Extension; SUPF: supplemental follow-up.
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(min.–max.: 14–85 days). In the CP 5.25 mg/kg group, 
four of the six patients who had Grade ⩾ 3 lymphope-
nia recovered, with a mean time to Grade 0–1 recovery 
of 34.9 (11.7) days (min.–max.: 26–51 days); lympho-
cyte count data were incomplete for the other two 
patients. The two groups treated with cladribine tablets 
in both CLARITY and the Extension (CC 7 and CC 
8.75 mg/kg) showed the highest incidence of Grade ⩾ 3 
lymphopenia (40.9% and 53.2%, respectively) and 
longest median time to recovery to Grade 0–1 lympho-
penia (212 and 168 days, respectively) during the 
Extension. The incidence rates of infections and infes-
tations showed no clear relation to total dose received 
(Table 3), with the exception of the herpes zoster 
infection rate which was higher in the CC 8.75 mg/kg 
group (4.8%) than the other groups (CC 7 mg/
kg = 1.1%, CP 3.5 mg/kg = 2.0%, CP 5.25 mg/kg = 1.1%, 
and PC 3.5 mg/kg = 2.0%; Table 3). The single case of 
“pulmonary mycosis” resulted from an erroneous cod-
ing of the reported term “pulmonary mycoplasmosis”; 
this event was non-serious, mild, and considered 
unrelated to study medication by the investigator. There 
were no cases of aspergillus in CLARITY Extension. 
The “fungal infection” was considered non-serious, 
and no specific location was reported.
Overall, 11/806 (1.4%) patients from the safety popu-
lation developed a malignancy or unspecified tumor 
(see Supplementary Table 3). No cases of progressive 
multifocal leukoencephalopathy (PML) occurred dur-
ing the Extension. Three deaths occurred during the 
Extension: two in the CP 3.5 mg/kg group (one drown-
ing and one unknown cause) and one in the CC 7 mg/
kg group (craniocerebral injury). All were considered 
unrelated or unlikely to be related to treatment with 
cladribine tablets (Table 2).
Efficacy outcomes
During the Extension, ARR were broadly similar 
across treatment groups (Table 4), and between-group 
Table 1. Baseline demographics and disease characteristics of treatment groups in CLARITY Extension (ITT population).
CP 3.5 mg/kg 
(n = 98)
CP 5.25 mg/kg 
(n = 92)
CC 7 mg/kg 
(n = 186)
CC 8.75 mg/kg 
(n = 186)
PC 3.5 mg/kg 
(n = 244)
Age, years 40.7 (10.7) 40.8 (9.6) 40.6 (10.5) 41.4 (10.1) 41.6 (9.6)
Female, n (%) 67 (68.4) 59 (64.1) 124 (66.7) 125 (67.2) 156 (63.9)
White, n (%) 96 (98.0) 90 (97.8) 181 (97.3) 180 (96.8) 240 (98.4)
Weight, kg 67.93 (14.89) 70.53 (15.16) 68.91 (14.09) 68.56 (14.01) 70.68 (15.56)
Prior DMD within 3 months of 
Study Day 1, n (%)
0 0 0 0 3 (1.2)
DMD use between CLARITY and 
Extension, n (%)
2 (2.0) 0 0 0 4 (1.6)
Number who relapsed between 
CLARITY and Extension,a n (%)
9 (9.2) 8 (8.7) 17 (9.1) 18 (9.7) 46 (18.9)
Disease duration,b years 10.07 (6.74) 12.30 (8.01) 10.41 (7.13) 11.85 (7.85) 10.80 (6.80)
Median EDSS score (min.; max.) 2.5 (0.0; 6.5) 2.5 (0.0; 6.5) 2.5 (0.0; 6.5) 2.5 (0.0; 6.5) 3.0 (0.0; 6.5)
Number of T1 Gd+ lesions 0.27 (0.96) 0.10 (0.49) 0.31 (1.56) 0.31 (1.29) 0.77 (1.85)
T1 Gd+ lesion volume, mm3 18.45 (68.14) 19.78 (108.84) 43.46 (245.13) 49.19 (266.98) 132.30 (415.18)
Number of T1 hypointense lesions 13.53 (13.39) 13.72 (15.84) 11.46 (12.66) 12.96 (14.66) 13.28 (14.35)
T1 hypointense lesion volume, 
mm3 × 103
2.39 (3.15) 3.50 (7.47) 1.95 (2.68) 2.37 (3.66) 2.31 (3.97)
T2 lesion volume, mm3 × 103 18.57 (19.05) 16.95 (18.17) 13.69 (14.39) 15.76 (14.55) 16.43 (13.81)
Mean gap between studies,c weeks 41.16 (26.13) 41.19 (25.86) 42.08 (25.37) 39.97 (23.89) 41.99 (27.47)
Median gap between studies,c 
weeks (min.; max.)
41.29 (0.1; 116.0) 43.07 (0.3; 112.9) 41.43 (0.4; 115.3) 39.50 (0.9; 111.0) 39.71 (0.3; 118.0)
ITT: intention-to-treat; CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine tablets 
5.25 mg/kg in CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by cladribine tablets 
3.5 mg/kg in CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; 
PC 3.5 mg/kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; DMD: disease-modifying drug; EDSS: Extended 
Disability Status Scale; Gd+: gadolinium-enhancing.
Data are shown as mean (standard deviation (SD)), unless stated otherwise.
aRelapses during the gap period were not qualified by an evaluating physician.
bTime from first attack.
cDuration of the gap between the last visit date in the CLARITY treatment period and the randomization date in CLARITY Extension.
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comparisons confirmed that there were no significant 
differences (Table 5). Proportions of relapse-free 
patients were also comparable across treatment 
groups. At the end of the CLARITY study, approxi-
mately 80% of patients who received cladribine tab-
lets 3.5 mg/kg were relapse-free.2 In patients from the 
group that received placebo in the Extension (i.e. the 
CP 3.5 mg/kg group), approximately 75% remained 
relapse-free at 120 weeks (Table 4). No significant 
differences in time to first qualifying relapse (relative 
to first dose) were seen between treatment groups 
during the Extension (Figure 3). However, there was 
a consequence to delaying treatment with cladribine 
tablets; when CLARITY and the Extension phase 
were considered together, the shortest time to first 
qualifying relapse was seen in patients treated with 
placebo in CLARITY and cladribine tablets 3.5 mg/kg 
in the Extension (PC 3.5 mg/kg, Supplementary 
Figure 1). The proportions of patients who did not 
experience 3-month confirmed EDSS progression 
ranged from 72.4% (CP 3.5 mg/kg group) to 78.3% 
(CP 5.25 mg/kg group), with no clear pattern of differ-
ences between treatment groups (Table 4). Median 
EDSS scores by visit and treatment groups during 
CLARITY and CLARITY Extension are shown in 
Supplementary Figure 2.
In an effort to evaluate the longitudinal effect of clad-
ribine on ARR, we compared the same groups of 
patients from the end of CLARITY to the end of 
CLARITY Extension. The only difference was 
observed in the PC 3.5 mg/kg group. Compared with 
placebo treatment during CLARITY (ARR 0.26), a 
significant reduction was seen when these patients 
received cladribine tablets 3.5 mg/kg during the 
Extension (ARR 0.10; 60.7% relative reduction, 
p < 0.0001). This difference in ARR was comparable 
to that seen between patients who received placebo 
and the group treated with cladribine tablets 3.5 mg/kg 
during the CLARITY study (57.6% relative reduction, 
Table 2. Overview of safety outcomes, including treatment-emergent adverse events reported in 5% or more of patients.
CP 3.5 mg/kg  
(n = 98)
CP 5.25 mg/kg  
(n = 92)
CC 7 mg/kg 
(n = 186)
CC 8.75 mg/kg 
(n = 186)
PC 3.5 mg/kg 
(n = 244)
All patients 
(N = 806)
All AEs 74 (75.5) 71 (77.2) 149 (80.1) 149 (80.1) 194 (79.5) 637 (79.0)
SAEs 16 (16.3) 8 (8.7) 25 (13.4) 23 (12.4) 22 (9.0) 94 (11.7)
Deathsa 2 (2.0) 0 1 (0.5) 0 0 3 (0.4)
AEs leading to treatment 
discontinuationb
3 (3.1) 4 (4.3) 26 (14.0) 30 (16.1) 26 (10.7) 89 (11.0)
Lymphopeniac leading to 
treatment discontinuation
0 1 (1.1) 22 (11.8) 23 (12.4) 17 (7.0) 63 (7.8)
Ten most frequently reported AEs (of those reported in 5% or more of patients)
 Lymphopenia 9 (9.2) 7 (7.6) 68 (36.6) 76 (40.9) 69 (28.3) 229 (28.4)
 Nasopharyngitis 19 (19.4) 15 (16.3) 22 (11.8) 28 (15.1) 45 (18.4) 129 (16.0)
 Headache 20 (20.4) 16 (17.4) 21 (11.3) 25 (13.4) 38 (15.6) 120 (14.9)
 Back pain 9 (9.2) 9 (9.8) 16 (8.6) 18 (9.7) 28 (11.5) 80 (9.9)
 Influenza 11 (11.2) 10 (10.9) 16 (8.6) 23 (12.4) 17 (7.0) 77 (9.6)
 Upper respiratory tract infection 8 (8.2) 9 (9.8) 17 (9.1) 20 (10.8) 19 (7.8) 73 (9.1)
 Urinary tract infection 6 (6.1) 4 (4.3) 17 (9.1) 16 (8.6) 17 (7.0) 60 (7.4)
 Leukopenia 1 (1.0) 2 (2.2) 19 (10.2) 20 (10.8) 12 (4.9) 54 (6.7)
 Pain in extremity 8 (8.2) 6 (6.5) 10 (5.4) 10 (5.4) 11 (4.5) 45 (5.6)
 Bronchitis 6 (6.1) 7 (7.6) 1 (0.5) 12 (6.5) 17 (7.0) 43 (5.3)
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine tablets 5.25 mg/kg in 
CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in 
CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/
kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; AE: adverse event; SAE: serious adverse event.
Data shown as n (%).
a Three deaths reported: two in the cladribine tablets/placebo (3.5 mg/kg) group (one drowning; one unknown cause) and one in the continuous cladribine tablets 
(7 mg/kg) group (craniocerebral injury). All cases were considered unrelated, or unlikely to be related, to the study medication.
b Overall incidences of AEs (n (% out of all patients)) leading to treatment discontinuation in ⩾2 patients, by System Organ Class (SOC) or preferred term, in the 
Extension study (safety population) were as follows: 62 (7.7%) blood and lymphatic disorders; 10 (1.2%) investigations; 4 (0.5%) infections and infestation; 
3 (0.4%) pregnancy, puerperium, and perinatal conditions; 3 (0.4%) skin and subcutaneous tissue disorders; 2 (0.2%) general disorders and administration-site 
conditions; 2 (0.2%) respiratory, thoracic, and mediastinal disorders.
cMain event (preferred term) leading to treatment discontinuation.
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p < 0.001).2 There were no clear relationships between 
the length of the gap period and the following: ARR, 
proportion of relapse-free patients, time to first quali-
fying relapse, or time to 3-month confirmed EDSS 
progression (data not shown). Data relating to MRI 
outcomes are the subject of a separate report.
Discussion
Overall, the safety and tolerability in CLARITY 
Extension were comparable with CLARITY, with 
lymphopenia the most frequently reported AE and the 
most frequent reason for treatment discontinuation, 
consistent with previous studies of cladribine tablets in 
RRMS.2 In CLARITY Extension, the majority of lym-
phopenia events were classified as mild or moderate, 
and the majority of patients who experienced lympho-
penia Grade ⩾ 3 actually experienced Grade 3 only. 
Furthermore, the majority of patients who experienced 
lymphopenia Grade ⩾ 3 recovered to Grade 0–1 lym-
phopenia by the end of the Extension. With the higher 
cumulative doses, the percentage of patients with 
Grade ⩾ 3 lymphopenia increased along with the time 
to recovery. Post-hoc analysis showed that in patients 
treated with cladribine tablets 3.5 mg/kg in CLARITY 
and cladribine tablets 3.5 mg/kg in CLARITY 
Extension according to the treatment guidelines (i.e. 
Grade 0 lymphocyte count at the start of CLARITY 
and Grade 0–1 at the start of Years 2, 3, and 4), no 
cases of Grade 4 lymphopenia were seen at the end of 
any treatment year. Furthermore, >85% of patients had 
recovered to Grade 0–1 lymphopenia by the end of 
Table 3. Overview of AEs of special interest (safety population).
CP 3.5 mg/kg 
(n = 98)
CP 5.25 mg/kg 
(n = 92)
CC 7 mg/kg 
(n = 186)
CC 8.75 mg/kg 
(n = 186)
PC 3.5 mg/kg 
(n = 244)
Incidence of lymphopenia (CTCAE Grade 3 or 4) and time to recovery
 Patients with Grade 3 or 4 lymphopeniaa 5 (5.1) 6 (6.5) 76 (40.9) 99 (53.2) 61 (25.0)
 Patients with Grade 4 lymphopenia 0 (0.0) 0 (0.0) 5 (2.7) 6 (3.2) 1 (0.4)
  Patients who recovered from Grade 3 or 4 
lymphopeniab
5 (100.0) 4 (66.7) 69 (90.8) 89 (89.9) 50 (82.0)
 Mean (SD) time to recoveryc (days) 41.0 (33.5) 34.9 (11.7) 256.7 (239.7) 241.80 (216.1) 160.2 (160.4)
 Median time to recovery (days) 22.00 31.50 212.00 168.00 111.3
 Min.–max. time to recovery (days) 14–85 26–51 8–1184 7–799 5–701
AEs and SAEs from SOC infections and infestations
 Any AE from SOC infections and infestations 48 (49.0) 44 (47.8) 91 (48.9) 87 (46.8) 110 (45.1)
 Serious AEs from SOC infections and infestations 2 (2.0) 2 (2.2) 2 (1.1) 3 (1.6) 7 (2.9)
Infections of interest in System Organ Class preferred terms (serious and non-serious)
 Herpes zoster 2 (2.0) 1 (1.1) 2 (1.1) 9 (4.8) 5 (2.0)
 Oral herpes 2 (2.0) 3 (3.3) 3 (1.6) 4 (2.2) 1 (0.4)
 Herpes simplex 1 (1.0) 0 1 (0.5) 0 2 (0.8)
 Herpes virus infection 1 (1.0) 0 0 0 2 (0.8)
 Genital herpes 0 0 0 1 (0.5) 0
 Varicella 0 0 0 0 1 (0.4)
 Candidiasis 0 0 1 (0.5) 0 0
 Fungal infection 0 0 1 (0.5) 0 0
 Hepatitis B 1 (1.0) 0 0 0 0
 Pulmonary mycosisd 0 0 0 1 (0.5) 0
 Tuberculosis (pulmonary) 0 0 0 1 (0.5) 0
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine tablets 5.25 mg/kg in 
CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in 
CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/
kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CTCAE: Common Terminology Criteria for Adverse Events; SD: 
standard deviation; AE: adverse event; SOC: System Organ Class.
Data shown as n (%), unless otherwise specified.
aDefined as an absolute lymphocyte count in CTCAE Grade 3–4 after initiating the Extension study.
bReturn of absolute lymphocyte count to CTCAE Grade 0 or 1.
cAnalysis conditional on a patient having a recovery event (recovery to CTCAE Grade 0/1) within the observation time of the study.
d The single case of “pulmonary mycosis” resulted from an erroneous coding of the reported term pulmonary mycoplasmosis; this event was non-serious, mild 
and considered unrelated to study medication by the investigator.
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each treatment year (not shown). The incidence of 
thrombocytopenia with cladribine tablets in CLARITY 
Extension was rare and similar to that in CLARITY, in 
which the only Grade 3 event was observed in the pla-
cebo group, in contrast to experience with higher rela-
tive doses of intravenous cladribine.2–4
No formal analysis of the association of infections 
with severity of lymphopenia was conducted for 
CLARITY Extension because of the potentially con-
founding effect from baseline status of study partici-
pants (i.e. pre-treated patients may have been 
lymphopenic for differing durations) and the overall 
Table 4. Summary of clinical efficacy endpoints.
CP 3.5 mg/kg 
(n = 98)
CP 5.25 mg/kg 
(n = 92)
CC 7 mg/kg 
(n = 186)
CC 8.75 mg/kg 
(n = 186)
PC 3.5 mg/kg 
(n = 244)
Annualized relapse rate (97.5% CI) 0.15 (0.09, 0.21) 0.13 (0.08, 0.19) 0.10 (0.06, 0.13) 0.12 (0.08, 0.16) 0.10 (0.07, 0.13)
Proportion of patients qualifying 
relapse-free, n (%)
68 (75.6) 61 (75.3) 134 (81.2) 132 (76.7) 180 (79.6)
Proportion of patients who remained 
free of confirmed 3-month EDSS 
progression, n (%)
71 (72.4) 72 (78.3) 144 (77.4) 142 (76.3) 185 (75.8)
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine tablets 5.25 mg/kg in 
CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in 
CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/
kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CI: confidence interval; EDSS: Expanded Disability Status Scale.
Data are mean (standard deviation (SD)), unless stated otherwise. The CLARITY Extension data in this table covers the 96-week double-blind period and the 
24-week supplemental follow-up (including the gap between periods). 
Table 5. Between-group analyses of clinical efficacy endpoints.
Group 1 vs Group 2 Pooled CC 7 + 8.75 mg/kgg 
(n = 372) vs Pooled CP 
3.5 + 5.25 mg/kgh (n = 190)
CC 7 mg/kg 
(n = 186) vs CP 
3.5 mg/kg (n = 98)
CC 8.75 mg/kg 
(n = 186) vs CP 
5.25 mg/kg (n = 92)
CP 3.5 mg/kg 
(n = 98) vs PC 
3.5 mg/kg (n = 244)
Annualized relapse rate
 Relative reductiona (%) 23.95 35.34 10.56 31.50
 Relative riskb 0.76 0.65 0.89 0.68
 97.5% CI 0.53, 1.10 0.39, 1.08 0.53, 1.51 0.42, 1.11
 p valuec 0.096 0.059 0.634 0.078
Proportion of patients qualifying relapse-free
 Odds ratiod 1.24 1.41 1.09 1.27
 97.5% CI 0.75, 2.05 0.69, 2.88 0.54, 2.21 0.65, 2.47
 p valuee 0.336 0.275 0.789 0.421
Time to confirmed 3-month EDSS progression
 Hazard ratiof 1.24 0.62 1.72 0.91
 97.5% CI 0.32, 4.78 0.30, 1.27 0.73, 4.05 0.48, 1.71
 p value 0.479 0.134 0.152 0.728
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CP 5.25 mg/kg: cladribine tablets 5.25 mg/kg in 
CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in 
CLARITY Extension; CC 8.75 mg/kg: cladribine tablets 5.25 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/
kg: placebo in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CI: confidence interval; EDSS: Expanded Disability Status Scale. 
The CLARITY EXT data in this table covers the 96-week DB and the 24-week SUPF (including the gap between periods). 
a The relative reduction was calculated as Group 2−Group 1 relative to Group 2, where Group 1 is the first group in the comparison and Group 2 is the second.
b Relative risk (rate ratio) due to treatment was estimated from a Poisson regression model with fixed effects for treatment group and region and log of time on 
study during Weeks 0–120 as an offset variable.
cp value based on Wald test of treatment effect from a Poisson regression model.
dOdds ratio due to treatment was estimated using a logistic regression model with fixed effects for treatment group and region.
ep value based on Wald test of treatment effect from logistic regression model.
f Hazard ratio due to treatment was estimated using a Cox proportional hazards model with fixed effects for treatment group and region; p value based on Wald 
test of treatment effect.
gCC 7 + 8.75 mg/kg; pooled data from the two groups that received active treatment in CLARITY and active treatment in the Extension.
hCP 3.5 + 5.25 mg/kg; pooled data from the two groups that received active treatment in CLARITY and placebo in the Extension.
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small numbers of events available for the analysis. 
Although the rate of herpes zoster infections was 
highest (4.8%) in the group that received the greatest 
cumulative dose of cladribine (CC 8.75 mg/kg), the 
group that received the next highest cumulative dose 
(CC 7 mg/kg) showed a rate of herpes zoster infec-
tions (1.1%) similar to or lower than the groups that 
received placebo in the Extension (CP 3.5 and 
5.25 mg/kg, 2.0% and 1.1%, respectively). In an inte-
grated analysis of safety data from the development 
program of cladribine in MS focusing on infections in 
association with severe lymphopenia, the incidence of 
herpes zoster (reported as an AE of special interest) 
was higher in the period of treatment in which Grade 
3 or 4 lymphopenia occurred until recovery to Grade 
1, compared to the time when the patients were not 
experiencing Grade 3 or 4 lymphopenia.5 Patients 
receiving cladribine tablets 3.5 mg/kg had adjusted 
AEs incidences of herpes zoster per 100 patient years 
(95% confidence interval (CI)) of 2.16 (0.90–5.19) 
during the period with Grade 3/4 lymphopenia, com-
pared to 0.75 (0.50–1.12) without lymphopenia.5 
There were no reports of PML during this study. It 
should be noted that despite observed cases of PML in 
patients treated with other formulations of cladribine 
for non-MS conditions,6 no cases of PML have been 
reported in clinical studies of patients with MS treated 
with cladribine tablets.
In this study, there was no clustering of particular 
malignancies with a common etiology, and no hema-
tological malignancies commonly associated with 
immunosuppression were seen. Overall, 1.4% of 
patients from the safety population developed a 
malignancy or unspecified tumor. Of interest, a recent 
independent meta-analysis of Phase 3 clinical trials 
showed that there was no significant difference in the 
malignancy rate observed with cladribine tablets in 
the CLARITY study compared with other studies of 
DMDs in MS and did not support an increased risk of 
malignancy with doses of cladribine used in the 
CLARITY study.7 In addition, Pakpoor et al.7 noted 
that the incidence in the CLARITY study placebo 
group was exceptionally low. In a separate analysis, 
malignancy incidences in the cladribine program 
were compared to data from a reference general popu-
lation as included in the GLOBOCAN epidemiologi-
cal database (for method used and information on 
non-melanoma skin cancer, which is not included in 
GLOBOCAN, please see Supplementary Materials). 
The analysis of the standardized incidence ratio (SIR) 
resulted in an overall malignancy rate in cladribine-
exposed subjects compared to a matched reference 
population of 1.06 (95% CI: 0.70; 1.55) indicating 
that the rate of malignancies in cladribine-treated 
patients was not higher than would have been expected 
in the general population. These findings support the 
Figure 3. Time to first qualifying relapse during CLARITY Extension. Time in months shown in 30-day increments. 
CP 3.5 mg/kg: cladribine tablets 3.5 mg/kg in CLARITY followed by placebo in CLARITY Extension; CC 7 mg/kg: cladribine tablets 
3.5 mg/kg in CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; CC 8.75 /kg: cladribine tablets 5.25 mg/kg in 
CLARITY followed by cladribine tablets 3.5 mg/kg in CLARITY Extension; PC 3.5 mg/kg: placebo in CLARITY followed by cladribine 
tablets 3.5 mg/kg in CLARITY Extension.
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need for more extensive registry studies to avoid 
potential confounding by low placebo group events 
and to more precisely determine the risk of malignan-
cies with DMDs. It is reassuring that this study 
showed no evidence of increased incidence of malig-
nancy over time (Supplementary Table 3).
Patients who received placebo in CLARITY had an 
increased ARR, a lower relapse-free rate, and increased 
risk of 3-month confirmed EDSS progression when 
compared with patients receiving cladribine tablets 
during CLARITY,2 underlining the rationale for ear-
lier treatment with cladribine tablets. CLARITY 
Extension indicates that treatment with cladribine tab-
lets over 2 years, followed by 2 years of placebo, pro-
duced a durable clinical response (as measured from 
the end of CLARITY to the end of the Extension 
period): the response achieved at the end of CLARITY 
in the proportion of patients free from relapses or sus-
tained disability progression was maintained in the 
Extension. Importantly, there was no evidence of 
increased clinical activity (i.e. disease rebound) after 
treatment discontinuation (e.g. in the CP 3.5 mg/kg 
group), as reported for other therapies in MS with a 
direct effect on lymphocytes.8,9 The gap period 
between the CLARITY and Extension treatment peri-
ods (median duration 40.3 weeks) along with the 
SUPF indicate that efficacy was maintained for pro-
longed periods for some patients (up to 6.5 years since 
the beginning of the CLARITY study and almost 
5.5 years since the last administration of cladribine 
tablets), which is a clear indicator of the treatment 
effects based on cladribine’s mode of action.
One limitation of the Extension study is that patient 
numbers were restricted by enrolling patients from 
CLARITY; consequently, it was not powered for 
efficacy analyses. Also, the gap between CLARITY 
and the Extension was variable. However, since the 
gap was similar between treatment groups, the dura-
tion is expected to have had a minor influence on 
comparative outcomes. Because treatment with 
cladribine tablets leads to lymphocyte reduction 
and/or other noticeable differences in hematological 
parameters, it was essential that the treating physi-
cian but not the evaluating physician had access to 
such laboratory data in order to make safety assess-
ments. In this case, although treating physicians may 
become functionally unblinded to treatment assign-
ment (a challenge that applies in clinical trials of 
other DMDs), the blinding of evaluating physicians 
was maintained.
Overall, the safety and tolerability profile of cladrib-
ine tablets seen in this and previous studies,2,10,11 and 
the clinical benefits observed in CLARITY Extension, 
indicate a favorable risk–benefit ratio in RRMS. The 
short-duration dosing of cladribine tablets in Years 1 
and 2 resulted in a durable clinical response and pro-
vided substantial “treatment-free” periods for at least 
two additional years with no requirement for a DMD; 
various efficacy analyses indicate that the clinical 
benefits of cladribine tablets may persist beyond 
2 years of observation. On average, there was no sig-
nificant incremental benefit from additional treatment 
with cladribine tablets in Years 3 and 4, following the 
initial courses received in Years 1 and 2 of CLARITY. 
The short-duration posology and favorable risk–bene-
fit profile of cladribine tablets treatment may facili-
tate treatment adherence, a significant challenge for 
patients with MS.12
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